Stacey W. McCullough, PharmD, senior vice president of pharmacy at Tennessee Oncology, discussed strategies for managing high-cost treatments, the impact of me-too drugs, and how clinical pathways can help physicians make treatment decisions at the point of care.
Stacey W. McCullough, PharmD, senior vice president of pharmacy at Tennessee Oncology, discussed strategies for managing high-cost treatments, the impact of me-too drugs, and how clinical pathways can help physicians make treatment decisions at the point of care.
Transcript (slightly modified)
What strategies for managing high-cost treatments aren't working, or could use some improvement?
I think that putting all drugs in the same category is very difficult in that some agents maybe appropriate for patients to receive without any type of submission of paperwork, etc, into the insurance provider. Certainly we understand that there are restraints and that they need to be managed, but there could be concessions, particularly with certain agents that were deemed worthy of first-line treatment.
What is the impact that "me-too" drugs have on healthcare costs?
Me-too drugs, as they've come into the market and have been priced at a premium to the existing drugs, there is no incentive basically to differentiate between the products, so when doing that it's left to the individual prescriber to choose which drug they would prefer. Whereas there could be some differentiation made in the front end and put parameters in place as far as guidance. I believe that would be well received.
How can clinical pathways help with making treatment decisions and what efforts are being made to incorporate pathways into healthcare organizations?
Clinical pathways if done correctly can be very beneficial for practices, payers, and patients alike, in that they would give some guidance to the physician at the site of care. Phsyicians don't typically worry most about cost, they worry most about the patient, but some insight into the cost of therapy at the point of care would be very beneficial and I think it would help them in guiding some decisions.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More